Marilyn Huckans1, Bret Fuller2, Viva Wheaton3, Sarah Jaehnert3, Carilyn Ellis4, Michael Kolessar3, Daniel Kriz3, Jeanne Renee Anderson3, Kristin Berggren4, Hannah Olavarria5, Anna W Sasaki6, Michael Chang6, Kenneth D Flora7, Jennifer M Loftis8. 1. Research & Development Service, Portland VA Medical Center, 3710 SW U.S. Veterans Hospital Rd., Portland, OR 97239, USA; Mental Health and Clinical Neurosciences Division, Portland VA Medical Center, 3710 SW U.S. Veterans Hospital Rd., Portland, OR 97239, USA; Department of Psychiatry, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., Portland, OR 97239, USA. Electronic address: marilyn.huckans@va.gov. 2. Mental Health and Clinical Neurosciences Division, Portland VA Medical Center, 3710 SW U.S. Veterans Hospital Rd., Portland, OR 97239, USA; Department of Psychiatry, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., Portland, OR 97239, USA. 3. Research & Development Service, Portland VA Medical Center, 3710 SW U.S. Veterans Hospital Rd., Portland, OR 97239, USA; School of Professional Psychology, Pacific University, 190 SE 8th Ave., Hillsboro, OR 97123, USA. 4. Research & Development Service, Portland VA Medical Center, 3710 SW U.S. Veterans Hospital Rd., Portland, OR 97239, USA; Graduate Department of Clinical Psychology, George Fox University, 414 N. Meridian St. #V104, Newberg, OR 97132, USA. 5. Research & Development Service, Portland VA Medical Center, 3710 SW U.S. Veterans Hospital Rd., Portland, OR 97239, USA. 6. Gastroenterology Service, Portland VA Medical Center, 3710 SW US Veterans Hospital Rd., Portland, OR 97239, USA; Department of Internal Medicine, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., Portland OR 97239, USA. 7. Portland Gastroenterology Division, Oregon Clinic, 9280 SE Sunnybrook Blvd., Clackamas, OR 97015, USA. 8. Research & Development Service, Portland VA Medical Center, 3710 SW U.S. Veterans Hospital Rd., Portland, OR 97239, USA; Department of Psychiatry, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., Portland, OR 97239, USA.
Abstract
OBJECTIVE: To prospectively evaluate for changes in objective cognitive performance (attention, memory, and executive function) and psychiatric symptom severity (depression, anxiety, fatigue, and pain) in patients before, during and after interferon-alpha based therapy (IFN) for chronic hepatitis C virus infection (HCV). METHODS: 33 HCV+ adults were evaluated two months before IFN initiation (baseline), three months into IFN, and six months following IFN termination (IFN+ Group). 31 HCV+ adults who did not undergo IFN therapy were evaluated at baseline and six months later (IFN- Group). At each evaluation, participants completed the Neuropsychological Assessment Battery (NAB) Attention, Memory and Executive Functions Modules, the Beck Depression Inventory, Second Edition (BDI), Generalized Anxiety Disorder Inventory (GADI), Fatigue Severity Scale (FSS), and Brief Pain Inventory (BPI). RESULTS: Compared with the IFN- Group, the IFN+ Group experienced significantly (p<0.050) increased symptoms of depression, anxiety, fatigue and pain during IFN therapy relative to baseline. In the IFN+ Group, psychiatric symptoms generally returned to baseline levels following IFN termination. Sustained viral response was associated with significantly lower depression and fatigue. No significant changes in cognitive performance were observed. CONCLUSIONS: During IFN, patients with HCV evidence significantly increased psychiatric symptoms, including symptoms of depression, anxiety, fatigue and pain. These psychiatric symptoms are generally short-term and remit following IFN termination, with increased benefit if viral clearance is achieved. However, IFN is not associated with significant declines in objective cognitive performance during or following IFN.
OBJECTIVE: To prospectively evaluate for changes in objective cognitive performance (attention, memory, and executive function) and psychiatric symptom severity (depression, anxiety, fatigue, and pain) in patients before, during and after interferon-alpha based therapy (IFN) for chronic hepatitis C virus infection (HCV). METHODS: 33 HCV+ adults were evaluated two months before IFN initiation (baseline), three months into IFN, and six months following IFN termination (IFN+ Group). 31 HCV+ adults who did not undergo IFN therapy were evaluated at baseline and six months later (IFN- Group). At each evaluation, participants completed the Neuropsychological Assessment Battery (NAB) Attention, Memory and Executive Functions Modules, the Beck Depression Inventory, Second Edition (BDI), Generalized Anxiety Disorder Inventory (GADI), Fatigue Severity Scale (FSS), and Brief Pain Inventory (BPI). RESULTS: Compared with the IFN- Group, the IFN+ Group experienced significantly (p<0.050) increased symptoms of depression, anxiety, fatigue and pain during IFN therapy relative to baseline. In the IFN+ Group, psychiatric symptoms generally returned to baseline levels following IFN termination. Sustained viral response was associated with significantly lower depression and fatigue. No significant changes in cognitive performance were observed. CONCLUSIONS: During IFN, patients with HCV evidence significantly increased psychiatric symptoms, including symptoms of depression, anxiety, fatigue and pain. These psychiatric symptoms are generally short-term and remit following IFN termination, with increased benefit if viral clearance is achieved. However, IFN is not associated with significant declines in objective cognitive performance during or following IFN.
Authors: San Keller; Carla M Bann; Sheri L Dodd; Jeff Schein; Tito R Mendoza; Charles S Cleeland Journal: Clin J Pain Date: 2004 Sep-Oct Impact factor: 3.442
Authors: D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar Journal: J Clin Psychiatry Date: 1998 Impact factor: 4.384
Authors: Jennifer M Loftis; Juno Valerio; Jonathan Taylor; Elaine Huang; Rebekah Hudson; Patricia Taylor-Young; Michael Chang; Samuel B Ho; Eric Dieperink; Juan Luis Miranda; Peter Hauser Journal: Alcohol Clin Exp Res Date: 2018-06-28 Impact factor: 3.455
Authors: Felix Kleefeld; Sophie Heller; Patrick Ingiliz; Heiko Jessen; Anders Petersen; Ute Kopp; Antje Kraft; Katrin Hahn Journal: J Neurovirol Date: 2018-05-21 Impact factor: 2.643
Authors: Yena Lee; Mehala Subramaniapillai; Elisa Brietzke; Rodrigo B Mansur; Roger C Ho; Samantha J Yim; Roger S McIntyre Journal: Ther Adv Psychopharmacol Date: 2018-11-19
Authors: Jennifer M Loftis; Jonathan Taylor; Hans-Peter Raué; Mark K Slifka; Elaine Huang Journal: Behav Brain Res Date: 2016-06-04 Impact factor: 3.332